Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02876835 · ClinicalTrials.gov registry record · Phase 3
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,872
- Enrollment target
NCT02876835: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT02876835 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 3,872 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (402% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02876835, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,872 participants
- Enrollment target
Study Summary
The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
Primary Outcome
Time to MACE defined as time to first occurrence of Clinical Events Committee (CEC) adjudicated MACE (composite of all-cause mortality, non-fatal myocardial infarction \[MI\] and non-fatal stroke) was analyzed using a Cox proportional hazards regression model with treatment group, current erythropoiesis-stimulating agents (ESA) use at randomization and region as covariates. Time to the first occurrence was computed as (event date minus randomization date) plus (+) 1. The incidence rate per 100 p
Interventions
- DRUG Placebo
- DRUG Darbepoetin alfa
- DRUG Daprodustat
- DRUG Iron Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,872 participants |
| Start Date | 2016-09-27 |
| Est. Completion | 2021-04-19 |
| Phase | Phase 3 |
What the finished NCT02876835 record still lists
NCT02876835 is an interventional study that assigns participants to a tested intervention. Its 3,872 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (402% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02876835 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02876835 about?
NCT02876835 is a clinical study titled "Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)". The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
What is the current status of trial NCT02876835?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,872 participants. The study started on 2016-09-27. Estimated completion is 2021-04-19.
What interventions are being tested in trial NCT02876835?
The interventions under investigation include: Placebo (DRUG), Darbepoetin alfa (DRUG), Daprodustat (DRUG), Iron Therapy (DRUG).
Who is sponsoring clinical trial NCT02876835?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02876835's enrollment target sits among peer trials
3,872 65th of 2000 higher than 1,936 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07087613 · 3,850 participants
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
- NCT05919342 · 3,904 participants · NA
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF"
- NCT03936335 · 3,930 participants
An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
- NCT05879926 · 3,960 participants · Phase 3
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI